Highlights of this issue include a reading list on "Speech, Language & Hearing in Older Age” as well as updates from AGE-WELL, Baycrest, Brainxchange, Bruyere, Centre for Studies in Aging and Health, Gilbrea Centre for Studies in Aging, Institute for Life Course & Aging, Ontario Age-Friendly Communities Outreach Program, Ontario Neurotrauma Foundation, Ontario Osteoporosis Strategy, Regional Geriatric Program of Toronto and Schlegel-UW Research Institute for Aging (RIA).
Information about funding opportunities and calls for abstracts from the Canadian Association on Gerontology and Canadian Frailty Network are included.A number of upcoming events and educational opportunities are listed. Sign up to receive Linkages directly here.
On Feb. 21st 2019, Dr. Joanne Ho provided this in-person and online presentation where she discussed the pharmacology of cannabinoids, unique considerations for older adults and cannabis drug-drug interactions to consider with cannabinoids. Please note that the content included was based on the best evidence available at the time. A special edition reading list is available as a pdf featuring related resources.
FASTlinks is a series of web-based maps that display links for elder care services in South East Ontario organized into 10 common elder care domains. The 10 domains are organized by function, rather than disease diagnosis. FASTlinks was developed by the CSAH in collaboration with the Aging with Co-morbidities Network.
This publication summarizes the literature on the evidence of using endocannabinoid system medications and their ability to modulate neuroinflammation and oxidative stress in Alzheimer’s Disease. 15 pages. Last reviewed March 2019.
The authors described the findings of a cross-sectional study which provided empirical evidence that prolonged use of inhaled or ingested street cannabis in patients with MS is associated with poorer performance on cognitive domains commonly affected in this population. 8 pages. Last reviewed March 2019.
This publication describes the findings of a review of medical marijuana (1948-2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy and movement disorders. 8 pages. Last reviewed March 2019.
This article reviews the findings of a randomized, double-blind, placebo-controlled study that sought evidence for the efficacy of low-dose TCH in reducing neuropsychiatric symptoms of dementia. 9 pages. Last reviewed March 2019.